Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod and Radiotherapy in Mycosis Fungoides
NCT05838599Phase 1Recruiting
- Sponsor
- Northwestern University
- Start
- Jul 2023
- Primary completion
- Jun 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imiquimod in mycosis fungoides (MF), sponsored by Northwestern University. Primary endpoints: Modified Severity Weighted Assessment Tool at 8 weeks and Treatment-Emergent Adverse Events at 12 weeks. Started Jul 2023; status: recruiting.
02
Drugs
imiquimod
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT05838599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838599.